Table 2. Association of microRNA-222 expression level with clinicopathologic characteristics of breast carcinomas in entire study group.
| Characteristics | miR-222 expression level | p-value* | |
|---|---|---|---|
| Low, No. (%) | High, No. (%) | ||
| Age (yr) | 0.718 | ||
| <50 | 53 (54.1) | 51 (51.5) | |
| ≥50 | 45 (45.9) | 48 (48.5) | |
| T stage | 0.001 | ||
| T1 | 57 (58.2) | 35 (35.4) | |
| T2-T3 | 41 (41.8) | 64 (64.6) | |
| N stage | 0.824 | ||
| N0 | 55 (56.1) | 54 (54.5) | |
| N1-N3 | 43 (43.9) | 45 (45.5) | |
| Histologic grade | 0.003 | ||
| I, II | 64 (65.3) | 44 (44.4) | |
| III | 34 (34.7) | 55 (55.6) | |
| Lymphovascular invasion | 0.715 | ||
| Absent | 55 (56.1) | 53 (53.5) | |
| Present | 43 (43.9) | 46 (46.5) | |
| p53 overexpression | 0.105 | ||
| Absent | 79 (80.6) | 70 (70.7) | |
| Present | 19 (19.4) | 29 (29.3) | |
| Ki-67 index (%) | 0.003 | ||
| <20 | 67 (68.4) | 47 (47.5) | |
| ≥20 | 31 (31.6) | 52 (52.5) | |
| ER | 0.248 | ||
| Negative | 31 (31.6) | 24 (24.2) | |
| Positive | 67 (68.4) | 75 (75.8) | |
| PR | 0.813 | ||
| Negative | 37 (37.8) | 39 (39.4) | |
| Positive | 61 (62.2) | 60 (60.6) | |
| HER2 | <0.001 | ||
| Negative | 97 (99.0) | 62 (62.6) | |
| Positive | 1 (1.0) 37 | -37.4 | |
| Subtype | <0.001 | ||
| Luminal A | 63 (64.3) | 27 (27.3) | |
| Luminal B | 5 (5.1) | 50 (50.5) | |
| HER2+ | 0 | 18 (18.2) | |
| Triple-negative | 30 (30.6) | 4 (4.0) | |
miR-222=microRNA-222; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2.
*p-values were calculated by the chi-square or Fisher exact test.